Technology evaluation: EMD-273063, EMD Lexigen

Thumbnail
Date
2004
ICR Author
Author
Niculescu-Duvaz, I
Type
Journal Article
Metadata
Show full item record
Abstract
Technology evaluation: EMD-273063, EMD Lexigen EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen Research Center Corp (a subsidiary of Merck KGaA) and its sister company, EMD Pharmaceuticals Inc, for the potential treatment of neuroblastoma and melanoma, for which it is in preclinical and phase I clinical trials, respectively.
URI
https://repository.icr.ac.uk/handle/internal/1915
Collections
Subject
Targeted interleukin-2 therapy antiganglioside gd2 antibody severe combined immunodeficiency dependent cellular cytotoxicity human neuroblastoma metastases high-dose interleukin-2 activated killer-cells phase-i trial fusion protein plus interleukin-2
Research team
Gene & Oncogene Targeting
Language
eng
License start date
2004
Citation
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (5), pp. 559 - 566